DecisionView

About DecisionView

Founded in 2002, DecisionView operated as a developer of web-based clinical optimization solutions tailored for the life sciences industry. The firm was acquired by IMS Health Holdings on April 24, 2012, marking a significant milestone after a decade of operation and raising $32.8M in funding.

The company's core business revolved around enhancing the performance of clinical trials for pharmaceutical companies and other life sciences organizations. Its business model was primarily Software-as-a-Service (SaaS), offering its flagship product, StudyOptimizer, on a subscription basis for single or multiple trials, complete with hosting, implementation, and support services. This addressed a critical need in the market to accelerate drug development and lower operational costs by improving the predictability and efficiency of patient enrollment.

DecisionView's main offering, StudyOptimizer, was a web-based application that provided a centralized platform for clinical trial managers to plan, track, and forecast patient enrollment. The software aggregated patient recruitment data from disparate sources, utilizing predictive analytics to project enrollment trends and trial completion dates. Key features included advanced historical analysis, visualizations of enrollment patterns, and scenario modeling. A notable capability was the Enrollment & Treatment Cost Analysis, which automatically calculated and visualized planned versus projected costs over time and across different regions. The platform also offered DecisionView Enrollment Benchmarks, which provided anonymized, aggregated cross-industry performance data to help clients create more realistic trial plans. By 2012, the solution was used by 8 of the top 10 global pharmaceutical companies on over 1,250 studies.